A clear MedCore Somatropin 50 IU product profile that distinguishes the biological active substance and approved somatropin medicines from this separate research presentation.
EMA describes somatropin as a copy of naturally occurring human growth hormone produced using recombinant DNA technology. Somatropin-containing medicines have been authorized in Europe through centralised or national procedures for decades.1
U.S. regulatory records also list multiple approved prescription products containing somatropin, including Omnitrope, Humatrope, Norditropin and others. Those approvals apply to the specific reviewed medicines, not automatically to any separate product labeled as somatropin.2
The key trust signal is to distinguish an approved active substance and its authorized medicines from a separate MedCore research presentation.
EMA states that somatropin is recombinant human growth hormone and notes that somatropin-containing medicines have been authorized in the EU since the 1980s. Approved uses vary by specific medicine and product information.1
FDA label records list approved somatropin products such as Omnitrope, Humatrope, Norditropin and Zomacton, with product-specific BLAs and labeling.2
DailyMed identifies Omnitrope as somatropin and notes its initial U.S. approval in 1987. Its labeling applies to that specific prescription product.3
Information about approved somatropin medicines must not be used to imply that the MedCore 50 IU research presentation has the same approval, formulation, indications, dosing, safety profile or therapeutic equivalence.
MedCore HGH Somatropin is presented here as a 50 IU research product. Product-specific formulation, route, purity, batch and analytical information should only be stated when confirmed by MedCore documentation.
No equivalence with an authorized somatropin medicine is asserted. Product-specific values require MedCore documentation.
The page keeps approved-drug regulatory information separate from the MedCore product record, allowing future batch documentation to stand on its own evidence.
Strength-specific documentation preview for the MedCore HGH Somatropin research presentation.
These images are presented as sample product documentation and should not be interpreted as independently verified analytical certification. Product identity, batch data and analytical claims should be checked against original laboratory records.
Internal links connect adjacent endocrine and peptide research entities without merging their regulatory status.
Concise answers preserve the distinction between the active substance, authorized medicines and MedCore.
Regulatory sources explain the active substance and authorized medicines without transferring their status to the MedCore presentation. Last reviewed 2 September 2026.
EMA explanation of somatropin and regulatory history of somatropin-containing medicines.
Open EMA source ↗FDA label records showing multiple approved prescription products containing somatropin.
Open FDA label source ↗Official U.S. prescription labeling for a specific approved somatropin medicine.
Open DailyMed source ↗Review the documentation framework or contact MedCore for product-specific information.
